A multicenter, open study to assess the tolerability, pharmacokinetics and antitumor effect of bendamustine hydrochloride (SyB L-0501: 90 or 120 mg/m2/day) administered intravenously for two days in patients with indolent lymphoma

Trial Profile

A multicenter, open study to assess the tolerability, pharmacokinetics and antitumor effect of bendamustine hydrochloride (SyB L-0501: 90 or 120 mg/m2/day) administered intravenously for two days in patients with indolent lymphoma

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Sep 2007

At a glance

  • Drugs Bendamustine (Primary)
  • Indications B cell lymphoma
  • Focus Adverse reactions
  • Sponsors SymBio Pharmaceuticals
  • Most Recent Events

    • 20 Sep 2007 Status changed from in progress to completed.
    • 29 May 2007 Status changed from recruiting to in progress.
    • 26 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top